Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myozyme in Juvenile Late-Onset Pompe Disease
NCT00250939Phase 2Completed
- Sponsor
- Sanofi
- Start
- Feb 2005
- Primary completion
- Jul 2006
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alglucosidase alfa in Pompe disease, sponsored by Sanofi. Primary endpoints: Safety and Pharmacokinetics Profile of rhGAA at 74 weeks, Forced Vital Capacity at 74 weeks and 2 more. Started Feb 2005; status: completed.
02
Drugs
alglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT00250939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00250939.